THE USE OF EGFR AND HGFR AGONISTS AS ANTICANCER DRUGS ACTING ON TUMOUR CELLS OF CERTAIN PHENOTYPE

摘要

Current opinion is that anti-carcinogenic effects related to receptors such as EGFR or HGFR (MET) and their mutants may be achieved by means of blocking them. Though, there are situations in which anti-carcinogenic therapy may be based on activation of these receptors. Condition, under which the EGFR agonists exert their anti-carcinogenic effects is that cells treated with them should present high expression levels of activating heterodimerization-inducing EGFR mutant (EGFRMUTaktHET) and EGFRwt. Similarly, high expression level of HGFR and the activating heterodimerization-inducing EGFR mutant is possible. Anti-carcinogenic effects of EGFR agonists are also possible in cells showing over-expression of EGFR only, without increased level of the EGFR mutant (EGFRMUTaktHET), as well as anti-carcinogenic effects of HGFR agonists can be observed in cells showing over-expression of HGFR only, without increased level of the EGFR mutant (EGFRMUTaktHET).